Subsequent Events (Details Narrative) $ in Millions |
12 Months Ended | ||||
|---|---|---|---|---|---|
|
Mar. 04, 2022
USD ($)
|
Mar. 03, 2022
USD ($)
|
Feb. 11, 2022
shares
|
Nov. 19, 2021
ft²
|
Dec. 31, 2020
shares
|
|
| Subsequent Event [Line Items] | |||||
| Conversion of Stock, Shares Issued | 511,879 | ||||
| Aimmune Therapeutics Inc [Member] | |||||
| Subsequent Event [Line Items] | |||||
| Area of Land | ft² | 4,500 | ||||
| Lessee, Operating Sublease, Option to Extend | commencement date of January 1, 2022 and maturing on June 30, 2024 | ||||
| Subsequent Event [Member] | |||||
| Subsequent Event [Line Items] | |||||
| Litigation Settlement, Expense | $ | $ 425,000.0 | $ 0.4 | |||
| Conversion of Stock, Shares Issued | 60,855 |
| X | ||||||||||
- Definition Area of land held. No definition available.
|
| X | ||||||||||
- Definition The number of new shares issued in the conversion of stock in a noncash (or part noncash) transaction. Noncash is defined as transactions during a period that do not result in cash receipts or cash payments in the period. "Part noncash" refers to that portion of the transaction not resulting in cash receipts or cash payments in the period. Reference 1: http://fasb.org/us-gaap/role/ref/legacyRef
|
| X | ||||||||||
- Definition Description of terms and conditions of option to extend operating sublease. Reference 1: http://www.xbrl.org/2003/role/disclosureRef
|
| X | ||||||||||
- Definition Amount of litigation expense, including but not limited to legal, forensic, accounting, and investigative fees. No definition available.
|
| X | ||||||||||
- Definition Detail information of subsequent event by type. User is expected to use existing line items from elsewhere in the taxonomy as the primary line items for this disclosure, which is further associated with dimension and member elements pertaining to a subsequent event. No definition available.
|
| X | ||||||||||
- Details
|
| X | ||||||||||
- Details
|